U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H13NO3S2
Molecular Weight 319.399
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of EPALRESTAT

SMILES

CC(=C/C1=CC=CC=C1)\C=C2/SC(=S)N(CC(O)=O)C2=O

InChI

InChIKey=CHNUOJQWGUIOLD-NFZZJPOKSA-N
InChI=1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-

HIDE SMILES / InChI

Description

Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.28 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
KINEDAK

PubMed

Sample Use Guides

In Vivo Use Guide
50 mg, 3 times/day
Route of Administration: Oral
In Vitro Use Guide
Human umbilical vein endothelial cells were cultured for 48 h in glucose-rich (27.8 mM) medium. The increased neutrophil-endothelial cell adhesion and surface expression of intercellular adhesion molecule-1 (ICAM-1), P-selectin, and E-selectin on endothelial cells was inhibited by 10 microM of epalrestat.